Published in PLoS One on September 29, 2011
Phenotype, donor age and gender affect function of human bone marrow-derived mesenchymal stromal cells. BMC Med (2013) 1.33
Deterministic and stochastic approaches in the clinical application of mesenchymal stromal cells (MSCs). Front Cell Dev Biol (2014) 0.98
Are MSCs angiogenic cells? New insights on human nestin-positive bone marrow-derived multipotent cells. Front Cell Dev Biol (2014) 0.91
Ehrlichia chaffeensis Exploits Canonical and Noncanonical Host Wnt Signaling Pathways To Stimulate Phagocytosis and Promote Intracellular Survival. Infect Immun (2015) 0.79
Mesangiogenic Progenitor Cells Derived from One Novel CD64(bright)CD31(bright)CD14(neg) Population in Human Adult Bone Marrow. Stem Cells Dev (2016) 0.78
Nanotopography Induced Human Bone Marrow Mesangiogenic Progenitor Cells (MPCs) to Mesenchymal Stromal Cells (MSCs) Transition. Front Cell Dev Biol (2016) 0.75
ED-B fibronectin expression is a marker of epithelial-mesenchymal transition in translational oncology. Oncotarget (2016) 0.75
Transplanted human umbilical cord mesenchymal stem cells facilitate lesion repair in B6.Fas mice. J Immunol Res (2014) 0.75
Growth Factor Content in Human Sera Affects the Isolation of Mesangiogenic Progenitor Cells (MPCs) from Human Bone Marrow. Front Cell Dev Biol (2016) 0.75
Human adult mesangiogenic progenitor cells reveal an early angiogenic potential, which is lost after mesengenic differentiation. Stem Cell Res Ther (2017) 0.75
Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods (2001) 414.27
Multilineage potential of adult human mesenchymal stem cells. Science (1999) 66.19
The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored. Nucleic Acids Res (2010) 18.73
A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell (2008) 18.18
Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement. Cytotherapy (2005) 5.92
Identification of a subpopulation of rapidly self-renewing and multipotential adult stem cells in colonies of human marrow stromal cells. Proc Natl Acad Sci U S A (2001) 4.07
Wnt signaling and stem cell control. Cell Res (2008) 3.53
New POU dimer configuration mediates antagonistic control of an osteopontin preimplantation enhancer by Oct-4 and Sox-2. Genes Dev (1998) 3.43
SSEA-4 identifies mesenchymal stem cells from bone marrow. Blood (2006) 2.83
Wnt 3a promotes proliferation and suppresses osteogenic differentiation of adult human mesenchymal stem cells. J Cell Biochem (2004) 2.71
Signaling pathways governing stem-cell fate. Blood (2007) 2.38
Human alternatives to fetal bovine serum for the expansion of mesenchymal stromal cells from bone marrow. Stem Cells (2009) 2.19
The Wnt signaling inhibitor dickkopf-1 is required for reentry into the cell cycle of human adult stem cells from bone marrow. J Biol Chem (2003) 2.09
The monoclonal antibody SH-2, raised against human mesenchymal stem cells, recognizes an epitope on endoglin (CD105). Biochem Biophys Res Commun (1999) 1.97
Wnt signaling controls the fate of mesenchymal stem cells. Gene (2008) 1.92
Mesenchymal stem cell preparations--comparing apples and oranges. Stem Cell Rev (2007) 1.88
Wnt/beta-catenin signaling. Cytokine Growth Factor Rev (2000) 1.86
Human bone marrow mesenchymal stromal cells express the neural ganglioside GD2: a novel surface marker for the identification of MSCs. Blood (2007) 1.77
Increasingly complex: new players enter the Wnt signaling network. Bioessays (2002) 1.67
Heads or tails: Wnts and anterior-posterior patterning. Curr Biol (2001) 1.65
Isolation and characterization of rapidly self-renewing stem cells from cultures of human marrow stromal cells. Cytotherapy (2001) 1.55
Heterogeneity of mesenchymal stromal cell preparations. Cytotherapy (2008) 1.51
Effects of Wnt signaling on proliferation and differentiation of human mesenchymal stem cells. Tissue Eng (2004) 1.51
Patients with high bone mass phenotype exhibit enhanced osteoblast differentiation and inhibition of adipogenesis of human mesenchymal stem cells. J Bone Miner Res (2007) 1.48
Canonical and non-canonical Wnts differentially affect the development potential of primary isolate of human bone marrow mesenchymal stem cells. J Cell Physiol (2007) 1.46
Phenotypic characterization of distinct human bone marrow-derived MSC subsets. Ann N Y Acad Sci (2009) 1.28
Selective culture of mesodermal progenitor cells. Stem Cells Dev (2009) 1.06
Wnt signaling in the niche. Cell (2008) 1.05
Identification of a stroma-mediated Wnt/beta-catenin signal promoting self-renewal of hematopoietic stem cells in the stem cell niche. Stem Cells (2009) 1.00
Selection of CD271(+) cells and human AB serum allows a large expansion of mesenchymal stromal cells from human bone marrow. Cytotherapy (2009) 1.00
Constitutive expression of pluripotency-associated genes in mesodermal progenitor cells (MPCs). PLoS One (2010) 0.95
Identification and purification of mesodermal progenitor cells from human adult bone marrow. Stem Cells Dev (2009) 0.94
A molecular basis for human embryonic stem cell pluripotency. Stem Cell Rev (2005) 0.84
Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med (2007) 10.40
Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol (2009) 3.26
Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease. N Engl J Med (2016) 2.36
Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol (2008) 2.32
CD57+ T lymphocytes and functional immune deficiency. J Leukoc Biol (2009) 1.84
Human mesenchymal stem cells reduce mortality and bacteremia in gram-negative sepsis in mice in part by enhancing the phagocytic activity of blood monocytes. Am J Physiol Lung Cell Mol Physiol (2012) 1.74
Repeated courses of granulocyte colony-stimulating factor in amyotrophic lateral sclerosis: clinical and biological results from a prospective multicenter study. Muscle Nerve (2011) 1.54
Evaluation of BCRP and MDR-1 co-expression by quantitative molecular assessment in AML patients. Leuk Res (2004) 1.48
Evaluation of the MDR1, ABCG2, Topoisomerases IIalpha and GSTpi gene expression in patients affected by aggressive mantle cell lymphoma treated by the R-Hyper-CVAD regimen. Leuk Lymphoma (2007) 1.44
Cardiac effects of 3-iodothyronamine: a new aminergic system modulating cardiac function. FASEB J (2007) 1.34
Inclusion of rituximab in treatment protocols for non-Hodgkin's lymphomas and risk for progressive multifocal leukoencephalopathy. Oncologist (2010) 1.26
Suspension of bone marrow-derived undifferentiated mesenchymal stromal cells for repair of superficial digital flexor tendon in race horses. Tissue Eng (2007) 1.20
Progressive multifocal leukoencephalopathy: report of three cases in HIV-negative hematological patients and review of literature. Ann Hematol (2007) 1.16
False positive PET scanning caused by inactivated influenza virus vaccination during complete remission from anaplastic T-cell lymphoma. Ann Hematol (2007) 1.14
Torquetenovirus viremia kinetics after autologous stem cell transplantation are predictable and may serve as a surrogate marker of functional immune reconstitution. J Clin Virol (2010) 1.08
Bilateral primary renal lymphoma treated by surgery and chemotherapy. Nephrol Dial Transplant (2004) 1.07
Selective culture of mesodermal progenitor cells. Stem Cells Dev (2009) 1.06
Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi. Br J Haematol (2011) 1.06
Polyomaviruses other than JCV are not detected in progressive multifocal leukoencephalopathy. J Clin Virol (2009) 1.04
Enhancement of neurite outgrowth in neuronal-like cells following boron nitride nanotube-mediated stimulation. ACS Nano (2010) 1.01
Lithium and hematology: established and proposed uses. J Leukoc Biol (2008) 0.99
Effects of Aspergillus fumigatus gliotoxin and methylprednisolone on human neutrophils: implications for the pathogenesis of invasive aspergillosis. J Leukoc Biol (2007) 0.97
Prognostic role of minimal residual disease in multiple myeloma patients after non-myeloablative allogeneic transplantation. Leuk Res (2005) 0.97
Safety and efficacy of (90) yttrium-ibritumomab-tiuxetan for untreated follicular lymphoma patients. An Italian cooperative study. Br J Haematol (2013) 0.95
Constitutive expression of pluripotency-associated genes in mesodermal progenitor cells (MPCs). PLoS One (2010) 0.95
Identification and purification of mesodermal progenitor cells from human adult bone marrow. Stem Cells Dev (2009) 0.94
Morpho-functional characterization of human mesenchymal stem cells from umbilical cord blood for potential uses in regenerative medicine. Stem Cells Dev (2009) 0.93
Use of autologous human mesenchymal stromal cell/fibrin clot constructs in upper limb non-unions: long-term assessment. PLoS One (2013) 0.93
Bortezomib inhibits T-cell function versus infective antigenic stimuli in a dose-dependent manner in vitro. Leuk Res (2006) 0.91
Progressive multifocal leukoencephalopathy: a report of three cases in HIV-negative patients with non-Hodgkin's lymphomas treated with rituximab. Ann Hematol (2009) 0.90
Synergistic antiproliferative effect of arsenic trioxide combined with bortezomib in HL60 cell line and primary blasts from patients affected by myeloproliferative disorders. Cancer Genet Cytogenet (2010) 0.89
HOX and TALE signatures specify human stromal stem cell populations from different sources. J Cell Physiol (2013) 0.89
Consistent bone marrow-derived cell mobilization following repeated short courses of granulocyte-colony-stimulating factor in patients with amyotrophic lateral sclerosis: results from a multicenter prospective trial. Cytotherapy (2010) 0.89
Lenograstim reduces the incidence of febrile episodes, when compared with filgrastim, in multiple myeloma patients undergoing stem cell mobilization. Leuk Res (2010) 0.88
MDR1 polymorphism influences the outcome of multiple myeloma patients. Br J Haematol (2007) 0.87
2CdA chemotherapy and rituximab in the treatment of marginal zone lymphoma. Leuk Res (2009) 0.87
Acute myeloid leukemia and follicular lymphoma after very low dose radioiodine therapy for thyroid diseases. Haematologica (2007) 0.86
Barium Titanate Nanoparticles: Highly Cytocompatible Dispersions in Glycol-chitosan and Doxorubicin Complexes for Cancer Therapy. Nanoscale Res Lett (2010) 0.86
Radioimmunotherapy with radretumab in patients with relapsed hematologic malignancies. J Nucl Med (2012) 0.86
Rituximab as treatment for minimal residual disease in hairy cell leukaemia: extended follow-up. Br J Haematol (2008) 0.86
Human autologous plasma-derived clot as a biological scaffold for mesenchymal stem cells in treatment of orthopedic healing. J Orthop Res (2008) 0.86
Impaired function of gamma-delta lymphocytes in melanoma patients. Eur J Clin Invest (2011) 0.85
Effect of epirubicin-based chemotherapy and dexrazoxane supplementation on QT dispersion in non-Hodgkin lymphoma patients. Biomed Pharmacother (2005) 0.85
Quantitative molecular monitoring of BCR-ABL and MDR1 transcripts in patients with chronic myeloid leukemia during Imatinib treatment. Cancer Genet Cytogenet (2005) 0.85
Hairy Cell Leukemia. Curr Treat Options Oncol (2007) 0.84
Expansion of TcRalphabeta+CD3+CD4-CD8- (CD4/CD8 double-negative) T lymphocytes in a case of staphylococcal toxic shock syndrome. Acta Haematol (2004) 0.84
Fludarabine, Bortezomib, Myocet and rituximab chemotherapy in relapsed and refractory mantle cell lymphoma. Br J Haematol (2009) 0.84
Human dental pulp stem cells protect mouse dopaminergic neurons against MPP+ or rotenone. Brain Res (2010) 0.84
Progressive multifocal leukoencephalopathy: what's new? Neuroscientist (2010) 0.84
Cytoplasmic nucleophosmin in myeloid sarcoma occurring 20 years after diagnosis of acute myeloid leukaemia. Lancet Oncol (2006) 0.84
Altered bone development and turnover in transgenic mice over-expressing lipocalin-2 in bone. J Cell Physiol (2013) 0.84
Progressive multifocal leukoencephalopathy in a haploidentical stem cell transplant recipient: a clinical, neuroradiological and virological response after treatment with risperidone. Antiviral Res (2006) 0.83
WT1 expression levels at diagnosis could predict long-term time-to-progression in adult patients affected by acute myeloid leukaemia and myelodysplastic syndromes. Br J Haematol (2010) 0.83
Carboxy-terminal fragment of osteogenic growth peptide regulates myeloid differentiation through RhoA. J Cell Biochem (2004) 0.83
Gelatin/PLLA sponge-like scaffolds allow proliferation and osteogenic differentiation of human mesenchymal stromal cells. Macromol Biosci (2008) 0.83
Endothelial differentiation of mesenchymal stromal cells: when traditional biology meets mechanotransduction. Integr Biol (Camb) (2013) 0.82
Discordant lymphoma consisting of splenic mantle cell lymphoma and marginal zone lymphoma involving the bone marrow and peripheral blood: a case report. J Med Case Rep (2011) 0.82
Risk of multiple myeloma is associated with polymorphisms within telomerase genes and telomere length. Int J Cancer (2014) 0.82
Distribution of exogenous [125I]-3-iodothyronamine in mouse in vivo: relationship with trace amine-associated receptors. J Endocrinol (2012) 0.82
Kinetics of hematogones in bone marrow samples from patients with non-Hodgkin lymphomas treated with rituximab-containing regimens: a flow cytometric study. Int J Hematol (2015) 0.82
MDR1 diplotypes as prognostic markers in multiple myeloma. Pharmacogenet Genomics (2008) 0.82
Novel 3-iodo-8-ethoxypyrazolo[5,1-c][1,2,4]benzotriazine 5-oxide as promising lead for design of alpha5-inverse agonist useful tools for therapy of mnemonic damage. Bioorg Med Chem (2007) 0.82
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus doxorubicin and dexamethasone as induction therapy in previously untreated multiple myeloma patients. Acta Haematol (2012) 0.82
MDR1 C3435T polymorphism indicates a different outcome in advanced multiple myeloma. Acta Haematol (2009) 0.82
Abnormal phenotype of bone marrow plasma cells in patients with chronic myeloid leukemia undergoing therapy with Imatinib. Leuk Res (2010) 0.81
Changes In CD8+57+ T lymphocyte expansions after autologous hematopoietic stem cell transplantation correlate with changes in torquetenovirus viremia. Transplantation (2008) 0.81
The small peptide OGP(10-14) reduces proliferation and induces differentiation of TPO-primed M07-e cells through RhoA/TGFbeta1/SFK pathway. Med Sci Monit (2011) 0.81
Peripheral-type benzodiazepine receptor binding sites in platelets of patients with panic disorder associated to separation anxiety symptoms. Psychopharmacology (Berl) (2005) 0.81
Re: Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials. J Natl Cancer Inst (2009) 0.81
Bone and bone marrow interactions: hematological activity of osteoblastic growth peptide (OGP)-derived carboxy-terminal pentapeptide. II. Action on human hematopoietic stem cells. Leuk Res (2002) 0.81
Carboxy-terminal fragment of osteogenic growth peptide in vitro increases bone marrow cell density in idiopathic myelofibrosis. Br J Haematol (2003) 0.81
Rituximab as treatment for minimal residual disease in hairy cell leukaemia. Eur J Haematol (2004) 0.81
CD45 expression in low-grade B-cell non-Hodgkin's lymphomas. Leuk Res (2007) 0.81
ITF2357 interferes with apoptosis and inflammatory pathways in the HL-60 model: a gene expression study. Anticancer Res (2010) 0.81
Preparation and pharmacological characterization of trans-2-amino-5(6)-fluoro-6(5)-hydroxy-1-phenyl-2,3-dihydro-1H-indenes as D2-like dopamine receptor agonists. J Med Chem (2005) 0.80